Circulating Tumor DNA as a Predictive Biomarker for Clinical Outcomes With Margetuximab and Pembrolizumab in Pretreated HER2-Positive Gastric/ Gastroesophageal Adenocarcinoma; Daniel V. T. Catenacci, MD, and colleagues present findings from a study of cir

Press/Media: Press / Media

Period	2023 Apr 27

Media coverage

Title	Circulating Tumor DNA as a Predictive Biomarker for Clinical Outcomes With Margetuximab and Pembrolizumab in Pretreated HER2-Positive Gastric/ Gastroesophageal Adenocarcinoma; Daniel V. T. Catenacci, MD, and colleagues present findings from a study of cir
Media name/outlet	CancerNetwork
Country/Territory	United States
Date	23/4/27
URL	metabase.moreover.com/noarticleurl?type=psh&lni=683Y-79Y1-JCXN-V01M-00000-00
Persons	Jong Ryeul Sohn, Hae Chul Park, Jang Wook Sohn, Hong-rae Kim, Kwangtae Park, Jangwook Sohn